Clinical Trials in Salt Lake City

Showing 2321-2340 of 7,997 trials

Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Inflammatory Syndromes

NCT01106209

The purpose of this study is to characterize the time to maturation of neutrophil extracellular trap(NET) formation capability in polymorphonuclear leukocytes(PMNs) isolated from newborn premature and term infants. Preterm infants who are enrolled into the study who then go on to require surgery \<1 year due to surgical NEC, will have the NET formation reassessed. This study will also determine whether NETs contribute to the pathogenesis of necrotizing enterocolitis (NEC). We hypothesize that NET formation contributes to the pathogenesis of NEC by inappropriately releasing degradative proteins and tissue destructive enzymes into the inflammatory milieu of the premature infant gastrointestinal tract following bacterial translocation. We also hypothesize that the delay in NEC development in premature infants (3rd - 4th week of life) as compared to at-risk term infants (1st week of life) results from a developmental delay in PMN ability to form NETs.

PrematurityNecrotizing Enterocolitis

University of Utah14 participantsStarted Apr 2010

Salt Lake City, Utah, United States • Salt Lake City, Utah, United States

COMPLETEDPhase 2< 1 mile

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

NCT02222155

The aim of this trial is to test the safety and efficacy of two dose regimens of the complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Funding Source - FDA OOPD

ANCA-associated Vasculitis

Amgen42 participantsStarted Feb 2015

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +40 more locations

Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Inflammatory Syndromes

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Find Trials by Condition in Salt Lake City

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

SNV1521 in Participants with Advanced Solid Tumors

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Optimizing Nutrition and Milk (Opti-NuM) Project

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

Brain Injury Rehabilitation Improving the Transition Experience

A Study of LY3561774 in Participants With Mixed Dyslipidemia